Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael Kalos

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

Immunity

English

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

English

Immunodynamics: A Cancer Immunotherapy Trials Network Review of Immune Monitoring in Immuno-Oncology Clinical Trials

Journal for ImmunoTherapy of Cancer

English

Targeting the TGFβ Pathway With Galunisertib, a TGFβRI SMI, Promotes Anti-Tumor Immunity Leading to Durable, Complete Responses, as Monotherapy and in Combination With Checkpoint Inhibition

Journal for ImmunoTherapy of Cancer

English

Adoptive Immunotherapy With Engineered T Cells Expressing and HLA-A2 Restricted Affinity-Enhanced TCR for LAGE-1 and NY-ESO-1 in Patients With Multiple Myeloma Following Auto-SCT

Journal for ImmunoTherapy of Cancer

English

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment

Cancer Research

Oncology

2012

English

Treatment of Advanced Leukemia in Mice With mRNA Engineered T Cells

English

HSP110 Improves the Anti-Tumor Effects of the Cytotoxic T Lymphocyte Epitope E749-57 in Mice: HSP110 as a Peptide Specific Chaperone or Adjuvant?

Cancer Biology and Therapy

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael Kalos

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Immunodynamics: A Cancer Immunotherapy Trials Network Review of Immune Monitoring in Immuno-Oncology Clinical Trials

Targeting the TGFβ Pathway With Galunisertib, a TGFβRI SMI, Promotes Anti-Tumor Immunity Leading to Durable, Complete Responses, as Monotherapy and in Combination With Checkpoint Inhibition

Adoptive Immunotherapy With Engineered T Cells Expressing and HLA-A2 Restricted Affinity-Enhanced TCR for LAGE-1 and NY-ESO-1 in Patients With Multiple Myeloma Following Auto-SCT

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Treatment of Advanced Leukemia in Mice With mRNA Engineered T Cells

HSP110 Improves the Anti-Tumor Effects of the Cytotoxic T Lymphocyte Epitope E749-57 in Mice: HSP110 as a Peptide Specific Chaperone or Adjuvant?